AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03457506 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Digital PET/CT scan
Description: The digital PET/CT scan will be acquired before or after the conventional PET/CT scan.
Study NCT03670329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: URGO2875
Description: Dressing
Study NCT01255007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR imaging
Description: Primovist enhanced MRI, Diffusion weighted MRI
Study NCT03804879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC)
Description: Optimal tolerated doses of angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)
Study NCT03804879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care (SoC)
Description: Optimal tolerated doses of angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)
Study NCT00479661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Continuous infusion
Study NCT00479661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Continuous infusion
Study NCT03858088 — intervention group
Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Liver transplantation from deceased donors
Study NCT00788151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine Serotypes 1, 2, 3, and 4
Description: 0.5 mL, Subcutaneous (SC)
Study NCT00788151 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine
Description: 0.5 mL, SC
Study NCT02450240 — intervention group
Intervention type: BEHAVIORAL
Intervention: self-report questionnaires
Study NCT00375895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclosporin
Description: ciclosporin administered orally twice a day, at the initial dosing of 2.5 mg/kg/d, adjusted to obtain a C2 concentration of 600 ng/ml associated with the usual ribavirin and PEGinterferon bitherapy.
Study NCT02318303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSP 301-1 NS (QD)
Description: GSP 301-1 NS (665 μg olopatadine hydrochloride/50 μg mometasone furoate) administered as 2 sprays/nostril
Study NCT02318303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSP 301-2 NS (BID)
Description: GSP 301-2 NS (665 μg olopatadine hydrochloride/25 μg mometasone furoate) administered as 2 sprays/nostril
Study NCT02318303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSP 301 Placebo NS
Description: GSP 301 placebo NS administered as 2 sprays/nostril
Study NCT02318303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine HCl-1 NS (QD)
Description: Olopatadine HCl-1 NS (665 μg) administered as 2 sprays/nostril
Study NCT02318303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine HCl-2 NS (BID)
Description: Olopatadine HCl-2 NS (665 μg) administered as 2 sprays/nostril
Study NCT02318303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate-1 NS (QD)
Description: Mometasone furoate -1 NS (50 μg) administered as 2 sprays/nostril
Study NCT02318303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate-2 NS (BID)
Description: Mometasone furoate-2 NS (25 μg) administered as 2 sprays/nostril
Study NCT02628886 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid
Description: pregnant women will be given intramuscular PCV 13 vaccine between 28-34 weeks
Study NCT02628886 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo 0.9% sodium chloride plus tetanus toxoid
Description: pregnant women will be given intramuscular saline injection between 28-34 weeks
Study NCT02628886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tetanus toxoid
Description: new born babies will be given PCV13 vaccine at birth
Study NCT02901977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Antihypertensive therapy
Study NCT01702376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retosiban 800 mg
Description: Subjects will be administered with single dose of one moxifloxacin placebo tablet and eight 100 mg tablets of retosiban
Study NCT01702376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be administered with one moxifloxacin placebo tablet and eight retosiban matched placebo tablets
Study NCT01702376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg
Description: Subjects will be administered with one 400 mg moxifloxacin tablet and eight retosiban matched placebo tablets
Study NCT02455557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02901977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxazosin
Description: Antihypertensive therapy
Study NCT05251610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20mg oral propranolol and oxytocin
Description: Participants will receive 20mg of oral propranolol 10minutes prior to initiation of augmentation or induction of labor with oxytocin
Study NCT05251610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin only
Description: Participants will have outright augmentation or induction of labor with oxytocin
Study NCT01791270 — intervention group
Intervention type: DEVICE
Intervention: Continuous positive airway pressure (CPAP) therapy
Description: Device: CPAP accordingly to the normal therapy in daily practice. In the group of 61 patients with OSA: we compared the results before and after three months of correct treatment with CPAP.~First, an automatic continuous positive airway pressure device (autoCPAP REMstar) was used to evaluate the pressure titration by night registration at patient home. AutoCPAP gets complete information about the optimum level to be set as therapeutic (CPAP pressure).~The patient has been reevaluated periodically in the outpatient Sleep Unit to verify proper adaptation and compliance of CPAP.~We considered a proper compliance when patients used CPAP ≥ 4 hours/day. This data has been extracted from the counter included in the CPAP compressor.~Procedures:~1. - Respiratory Polygraphy~2. - Ambulatory Blood Pressure Monitoring~3. - Endothelial dysfunction, by determining the hyperaemic response to ischemia using a Laser-Doppler flowmeter.~4. - ß1en subunit expression in peripheral blood leukocytes.
Study NCT01328379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalfampridine-ER 5mg
Description: 5mg, twice daily
Study NCT01328379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalfampridine-ER 10mg
Description: 10mg, twice daily
Study NCT01328379 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, twice daily
Study NCT02735785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harnessing Online Peer Education (HOPE) Social Media Intervention
Study NCT02500576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV or SC
Study NCT02500576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02500576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IVPB
Study NCT02500576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02500576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02500576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02450240 — intervention group
Intervention type: BEHAVIORAL
Intervention: behavioral tasks
Study NCT02450240 — intervention group
Intervention type: OTHER
Intervention: physiological measurements
Study NCT02450240 — intervention group
Intervention type: OTHER
Intervention: structural and functional magnetic resonance imaging and EEG
Study NCT02450240 — intervention group
Intervention type: OTHER
Intervention: biomarker and microbiome assessments
Study NCT02450240 — intervention group
Intervention type: OTHER
Intervention: blood to derive induced pluripotent stem cells
Study NCT02450240 — intervention group
Intervention type: OTHER
Intervention: genetic and epigenetic assessments
Study NCT00671411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasound with intravenous microbubble contrast injection
Description: Intravenous line will be inserted. After the ultrasound microbubble contrast has been suspended into solution, contrast will be injected intrav via hand bolus with a total activated suspension of 0.2 mL (30 uL octaflouropropane),followed by 10 mL saline flush, with option to rebolus 4 addit time's for tot dose of 150 uL. Post contrast cine images of renal mass will be obtained on commercially available US units primarily using low mechanical index settings \& Contrast Pulsed Sequence (CPS®) technique. Images will be acquired at predetermined intervals, for up to 8 min post contrast admin. Manufacturer's guidelines incl immediate post flush image capture, as well as post admin image capture at intervals as 1 min, 2 , 4 \& 8 mins. Additional, temporary higher mechanical index imaging of kidney for the purpose of flash bubble destruction may be optionally triggered using manufacturer's preset settings \& energy w/i FDA guidelines. This will only be performed while imaging the kidney.
Study NCT00599222 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: ranibizumab
Description: 0.5 mg intravitreal injection
Study NCT00599222 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 0.5 mg intravitreal injection
Study NCT00599222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TTT
Description: Transpupillary thermotherapy (TTT)
Study NCT00599222 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham TTT
Description: Sham Transpupillary thermotherapy (TTT)
Study NCT02396264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mediterranean diet
Description: 50 pcos women will be assigned to normocaloric mediterranean diet for 6 months
Study NCT02396264 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normocaloric diet
Description: 50 pcos women will be assigned to standardized normocaloric diet for 6 months
Study NCT01774227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The pops-titration group
Description: The energy delivery is started at a low level and is increased in intervals till an audible pop is heard, following which the power is reduced downward until the pops are no longer audible, then the treatment is completed at these parameters
Study NCT01774227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The slow-coagulation group
Description: The Gaasterland's slow-coagulation energy delivery technique using the lower power for the longer duration.
Study NCT00193726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab Premarin (Ethinyl estradiol)
Description: Tab Premarin 0.625 mg (Ethinyl estradiol) once a day for 5 days prior to each cycle of chemotherapy
Study NCT00193726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once a day for 5 days prior to each cycle of chemotherapy
Study NCT02500576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Tumor Infiltrating Lymphocytes
Description: Given IV
Study NCT02455557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Given SC
Study NCT02455557 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study NCT01565785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The FSM-DPI.
Description: Nurses will assess key elements of family self-management (home care, child's care, practice, medications, watching child, recovery, development, family adjustment and parental support) and address any deficits to facilitate effective discharge and family management of child at home after hospitalization.
Study NCT02564042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 1% Cream
Description: 1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
Study NCT02455557 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SVN53-67/M57-KLH Peptide Vaccine
Description: Given SC
Study NCT02455557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO or IV
Study NCT02290158 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Finishing Protocol
Description: Students education, cast models and Panoramic X-ray assessment, brackets reposition and frequent clinical evaluation.
Study NCT00293761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost, Investigational
Description: One drop in study eye once daily for 13 days
Study NCT00293761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost (TRAVATAN)
Description: One drop in study eye once daily for 13 days
Study NCT03510195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEDICORP HO PREPARATORY MODULE
Description: 3 DAY course module to prepare medical graduates to become house officers
Study NCT01046292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba
Description: The participants will be randomly allocated to either the intervention group or the placebo control group at a ratio of 1:1. After six months, GBE will be administered to all participants for another 6 months for free. The daily administered dose (taken with meals in the morning and evening) will consist of either twice-daily 1 capsule of Symfona® forte 120mg GBE or identically appearing placebo.
Study NCT01046292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ginkgo biloba
Description: The participants will be randomly allocated to either the intervention group or the placebo control group at a ratio of 1:1. After six months, GBE will be administered to all participants for another 6 months for free. The daily administered dose (taken with meals in the morning and evening) will consist of either twice-daily 1 capsule of Symfona® forte 120mg GBE or identically appearing placebo.
Study NCT03451422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavaleukin Alfa
Description: Efavaleukin Alfa will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.
Study NCT03451422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.
Study NCT04094142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib, lenalidomide, rituximab will be given as described in the Arms decriptions. Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, for 6 cycles.~After 6 cycles, maintenance of acalabrutinib 100mg bid will be administered up to 1 year for subjects whose best responses- to the regimen are partial response or complete remission.
Study NCT02981407 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Red Blood Cell Transfusion
Description: Transfusion of packed red blood cell units
Study NCT01913665 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: B.lactis
Study NCT01913665 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Study NCT01913665 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: B.Lactis +Inulin
Study NCT01913665 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01276444 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Swan-Ganz catheter
Description: the data s=derived from PAC included pulmonary artery occlusion pressure etc
Study NCT01276444 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transpulmonary thermodilution + central venous saturation
Description: Described in details above
Study NCT00610441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8777
Study NCT00610441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK-8777
Study NCT00610441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00610441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04511117 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: ProTaper Next rotary system and iRoot SP sealer with composite restorations.
Study NCT04511117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endocrown group
Description: ProTaper Next rotary system and iRoot SP sealer with endocrown restorations.
Study NCT02388594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZFN Modified CD4+ T Cells
Study NCT02388594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT03655327 — intervention group
Intervention type: OTHER
Intervention: reach to grasp a cup
Description: reach to grasp a cup of different weights located at different heights of table
Study NCT01628614 — intervention group
Intervention type: OTHER
Intervention: Standard of Care
Description: Patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
Study NCT02590822 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cambridge Weight Plan
Description: Group receives a total meal replacement diet from Cambridge Weight Plan containing 810 kcal/day (40% protein, 50% carbohydrate, 10% fat). As 3 or 4 mini-meals daily in flavoured formula food packets made up with water, milk or non-dairy alternative; or as snack bars based on preference. Supplemented with up to three portions of non-starchy vegetables and 2 litres of water, or other non-calorific drinks, per day. Participants to abstain from alcohol for study duration. The diet will be stopped, and a maintenance diet re-introduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first.~The TDR will be undertaken alongside health behaviour coaching and relapse prevention through weekly, where possible, contact (telephone or face-to-face) with a qualified dietician or equivalent.~Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study.
Study NCT02590822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Sessions
Description: The exercise group will attend supervised exercise sessions at the Leicester-Loughborough Diet, Lifestyle and Physical Activity (LLP) BRU or at the Leicester Diabetes Centre. The exercise program will typically consist of a thrice weekly, 60 minute session of moderate intensity aerobic exercise, in line with prevailing guidelines. An initial assessment of cardiorespiratory fitness will be performed, and exercise intensity titrated to aim for a workload of approximately 60% of the patient's VO2 max.~Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study.
Study NCT04937335 — intervention group
Intervention type: OTHER
Intervention: intratumoral hemorrhage
Description: Patients who were recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation were enrolled in the hemorrhage group.
Study NCT03594916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.
Study NCT03594916 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
Study NCT02564042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 0.5% Cream
Description: 0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
Study NCT02564042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: White to off-white vehicle cream base to be applied topically
Study NCT02742584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cough Stress Test
Description: Varying bladder volumes during cough stress test.
Study NCT03158506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: \[14C\]-labelled HMS5552
Study NCT01752699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.
Study NCT01752699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: patients with post-herpetic neuralgia take placebo to treat the pain symptoms.
Study NCT03744026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonoCloud-9
Description: Escalating numbers of ultrasound beams at constant acoustic pressure
Study NCT03744026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Dose of carboplatin infusion is AUC4-6